Liver transplant in primary sclerosing cholangitis: Current trends and future directions

Table 2 Overview of the clinical scores for predicting prognosis in primary sclerosing cholangitis and its components that include serum-based biomarkers and clinical features

Clinical scores	Components
Mayo risk score	Age, bilirubin, histological stage, hemoglobin and presence of inflammatory bowel disease
Revised Mayo risk score	Age, bilirubin, albumin, aspartate aminotransferase and variceal bleeding
Amsterdam–Oxford model	Primary sclerosis cholangitis (PSC) subtype, age at PSC diagnosis, albumin, alkaline phosphatase, aspartate aminotransferase, bilirubin and platelets
Short-term United Kingdom-pSC risk score	Bilirubin, albumin, hemoglobin, and platelets count at diagnosis
Long-term United Kingdom-pSC risk score	Age at diagnosis, bilirubin at the second year, alkaline phosphatase at the second year, albumin at the second year, platelets at the second year, presence of extrahepatic biliary disease at diagnosis, and variceal hemorrhage by the second year
Primary sclerosing cholangitis risk estimate tool	Bilirubin, albumin, alkaline phosphatase, platelets, aspartate transaminases, hemoglobin, sodium, PSC duration and age
Model for end stage liver disease	Dialysis at least twice in the past week, creatinine, bilirubin, international normalized ratio and sodium
Child-Pugh score	Bilirubin, albumin, international normalized ratio, ascites and encephalopathy